Cronos Group Releases 2025 Second Quarter Results

Cronos Group Inc. (NASDAQ:CRON)  is among the 12 Best Marijuana Stocks to Buy According to Analysts. Cronos Group Inc. (NASDAQ:CRON) announced $33.5 million in net revenue for the second quarter of 2025, a 21% jump year over year. The growth was due to booming cannabis flower sales in Israel and international markets, Cronos GrowCo consolidation, and stronger Canadian extract sales. The gross profit increased from $8.2 million in the second quarter of 2024 to $14.5 million. Adjusted EBITDA climbed by $12.7 million from the previous year to $1.7 million. Cronos reported a net loss of $38.5 million despite sales growth and efficiency benefits.

Cronos Group Inc. (NASDAQ:CRON)’s PEACE NATURALS® retained its position as Israel’s leading cannabis brand, driving record sales in the country. CEO Mike Gorenstein noted planned flower capacity growth and strong global momentum to alleviate supply limitations in Canada. This quarter’s flower sales brought roughly $2.2 million for Cronos GrowCo. The firm maintains a strong balance sheet with $834 million in cash and no debt, allowing it to support international growth and innovation in brands including Lord Jones® and Spinach®. It is one of the Best Marijuana Stocks.

While we acknowledge the potential of CRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.